Loading...
01/11 03:12
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Despite strong revenue growth and improved medical margins, the company faces challenges such as declining revenue guidance for 2025 and ongoing losses in Part D. The Q&A section highlighted concerns about cost trends and management's lack of clarity on certain issues. The market cap suggests moderate volatility, leading to a neutral rating as positive developments are offset by uncertainties and financial pressures.
MA Membership 527,000 members, a 36% increase year-over-year, driven by the expansion of the '24 partner class and 4.1% same geography growth.
Total Revenue $1.52 billion for Q4 2024, a 44% increase year-over-year; $6.06 billion for the full year, a 40% increase year-over-year, primarily driven by the class of '24 and organic growth, partially offset by higher Medicare Part-D costs and lower risk adjustment revenue.
Medical Margin $1 million for Q4 2024, compared to a negative $102 million in Q4 2023; $205 million for the full year 2024, down from $299 million in 2023, impacted by prior year development and elevated medical cost trends.
Adjusted EBITDA -$84 million for Q4 2024, an improvement from -$137 million in Q4 2023; -$154 million for the full year 2024, compared to -$95 million in 2023, driven by elevated medical cost trends and unfavorable prior year development.
G&A Expense $60 million for Q4 2024, down from $65 million in Q4 2023; $269 million for the full year, down from $286 million in 2023, reflecting lower geography entry costs and capital support.
Cash and Marketable Securities $406 million at the end of Q4 2024, with an additional $36 million off-balance sheet cash held by ACO entities.
Medical Expense $1.52 billion for Q4 2024, a 31% increase year-over-year, driven by membership growth and elevated cost trends; for the full year, medical services expense increased 46% due to average membership growth and elevated medical cost trends.
2025 Revenue Guidance Expected to decline 2% to approximately $5.925 billion, driven by membership decline and offset by better revenue yield from improved payor contracts.
2025 Medical Margin Guidance Expected to improve 46% to $300 million at the midpoint, reflecting a lower starting point due to elevated costs and prior year development.
2025 Adjusted EBITDA Guidance Expected to be -$75 million at the midpoint, driven by medical margin guidance and flat G&A costs.
Medicare Advantage Membership Growth: MA membership increased 36% year-over-year to 527,000 members, driven by the expansion of the '24 partner class and 4.1% same geography growth.
ACO Model Membership Growth: ACO model membership was 132,000 members, slightly ahead of expectations, representing a 48% year-over-year growth.
2025 Membership Guidance: 2025 MA membership is projected to decline by approximately 4% to a range of 490,000 to 520,000 members, including a smaller class of 2025 from 3 new partners.
Operational Efficiencies: Actions taken to reduce underwriting exposure to costs outside control, including reducing Medicare Part-D exposure to less than 30% of membership.
Cost Discipline: Maintained operating cost discipline by leveraging scaled infrastructure and technology investments.
Clinical Strategy Investments: Investments in clinical strategy to improve quality outcomes and operational performance.
Strategic Shift in Membership Growth: A strategic decision to constrain 2025 MA membership to balance near-term risks and opportunities.
Focus on Quality Performance: Increased incentives tied to delivering 4-plus stars performance in 2025 payor contracts.
Exit Underperforming Partnerships: Exited 2 unprofitable partnerships to improve bottom line profitability and cash burn.
Medicare Advantage Rate and Utilization Cycle: The company is navigating a difficult Medicare Advantage rate and utilization cycle, which presents ongoing challenges for financial performance.
Medicare Part D Exposure: The company has reduced its Medicare Part D exposure to less than 30% of its membership to mitigate risks associated with costs outside its control.
Membership Decline: A projected decline in Medicare Advantage membership by approximately 4% or 22,000 members in 2025 due to partnership exits and contract terminations.
Elevated Cost Trends: The Medicare Advantage market is experiencing elevated cost trends, which are expected to continue impacting financial performance in 2025.
Regulatory Changes: Changes related to the Inflation Reduction Act and increased quality bonus thresholds are embedded in the company's 2025 outlook, posing additional challenges.
Underperforming Partnerships: The company has exited unprofitable partnerships and underperforming payor contracts, which, while improving profitability, also indicates prior risks in partnership management.
Cash Flow and Profitability Goals: The company aims to achieve cash flow breakeven by 2027, indicating ongoing financial pressures and the need for strategic actions to improve performance.
Cost Management: The company is focused on maintaining operating cost discipline while investing in technology and clinical programs, highlighting the challenge of balancing growth with cost control.
Membership Strategy: In 2025, Agilon Health anticipates a full year Medicare Advantage (MA) membership decline of approximately 4% or 22,000 members, targeting a range of 490,000 to 520,000 members. This includes adding 20,000 members from a smaller class of 2025 and a 3% same geography growth.
Revenue Forecast: For 2025, total revenue is forecasted to decline 2% to approximately $5.925 billion, driven by the membership decline but offset by improved revenue yield from better payor contracts.
Medical Margin: Medical margin is expected to improve 46% to $300 million at the midpoint for 2025, reflecting a lower starting point due to elevated costs.
Adjusted EBITDA: Adjusted EBITDA guidance for 2025 is expected to be negative $75 million at the midpoint, assuming flat G&A costs.
Cash Flow Breakeven Goal: Agilon aims to achieve cash flow breakeven by 2027.
Clinical Strategy Investments: Continued investments in clinical strategy and capabilities to enhance quality outcomes and operational performance.
2025 MA Membership: Expected MA membership of 505,000 at the midpoint, with a decline due to partnership exits and contract terminations.
2025 Revenue Guidance: Projected revenue range of approximately $5.83 billion to $6.03 billion for 2025.
2025 Medical Margin: Expected medical margin in the range of $275 million to $325 million, with a midpoint of $300 million.
2025 Adjusted EBITDA: Expected adjusted EBITDA loss of $75 million at the midpoint.
Cost Trend: Estimated gross cost trend for 2025 is 6.3%, with net cost trend at 5.3%.
First Quarter Guidance: For Q1 2025, expected MA membership of 490,000 to 510,000, revenues of $1.48 billion to $1.52 billion, and medical margin of $125 million to $140 million.
Share Repurchase Program: None
The earnings call summary presents a mixed picture. While there are strategic plans for 2026, current issues like the negative impact of ACO REACH program changes and unclear management responses create uncertainty. The Q&A section highlights concerns about profitability and contract renewals, but also notes potential improvements in 2026. The market cap suggests moderate volatility, leading to a neutral sentiment as the stock may not significantly move in either direction over the next two weeks.
The earnings call summary reveals a mixed outlook. Financial performance and guidance are moderate, with some positive aspects like stable revenue guidance and quality incentives. However, concerns remain around negative EBITDA, cash usage, and cost pressures. The Q&A session highlights uncertainties in payer relationships and risk adjustments, but also confidence in liquidity and ACO REACH performance. Given the market cap and lack of strong catalysts, the stock price is likely to remain stable, resulting in a neutral prediction.
The earnings report highlights declining membership, revenue, and medical margins, indicating operational and financial challenges. The Q&A session revealed uncertainties regarding Medicare policy, payer negotiations, and drug pricing. Despite some optimism for 2026, the lack of a share repurchase program and absence of clear guidance on key financial metrics further contribute to a negative sentiment. Given the company's small market cap, these factors are likely to result in a stock price decrease of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
